Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




FAPI PET/CT Improves Staging of Newly Diagnosed Breast Cancer

By MedImaging International staff writers
Posted on 08 Jul 2024

18F-FDG PET/CT is commonly employed for staging breast cancer but faces challenges such as false positives in inflammatory breast lesions and reduced sensitivity in certain breast cancer subtypes. More...

Earlier small-scale retrospective studies have indicated that 68Ga-FAPI may surpass 18F-FDG PET/CT in detecting primary tumors and metastases in breast cancer patients due to its higher sensitivity. Now, a new comparative analysis between FAPI and 18F-FDG PET/CT for the systemic staging of newly diagnosed breast cancer has demonstrated that FAPI PET/CT offers more accurate staging. Notably, nearly 20% of patients had their clinical stage revised based on FAPI PET/CT findings, highlighting its potential benefits and efficacy in clinical settings.

The study by researchers at Peking Union Medical College Hospital (Beijing, China) included a total of 121 patients newly diagnosed with breast cancer. All participants underwent 18F-FDG imaging, and of these, 53 were also imaged using 68Ga-FAPI-04 PET/CT, while another 68 underwent A118F-FAPI-04 PET/CT. Lesions were considered positive if their uptake was higher than the surrounding tissue. The TNM clinical stage was assessed from both 18F-FDG and FAPI PET/CT images based on criteria from the American Joint Committee on Cancer Staging Manual. FAPI led to a restaging of 19.8% of patients when compared with stages determined by 18F-FDG PET/CT. The study also found that treatment plans were enhanced for six patients following the discovery of additional bone lesions and internal mammary lymph nodes. Notably, FAPI PET/CT identified a higher stage in 21.7% of patients initially classified as stage IIA by 18F-FDG PET/CT. Researchers suggest that patients with stage IIA breast cancer should consider undergoing systemic staging with FAPI PET/CT at the time of initial diagnosis.

“There is currently a lack of evidence on the efficacy of FAPI PET/CT, especially in large sample cohorts. Our study sought to add to the literature by assessing FAPI PET/CT for the systemic staging of newly diagnosed breast cancer compared with 18F-FDG PET/CT,” said Zhixin Hao, MD, a nuclear medicine physician at Peking Union Medical College Hospital. “This study is significant as it has the potential to advance personalized treatment strategies for breast cancer patients. FAPI PET/CT for the initial staging of breast cancer has the potential to reduce unnecessary treatments and improve patient outcomes.”

Related Links:
Peking Union Medical College Hospital


Diagnostic Ultrasound System
DC-80A
High-Precision QA Tool
DEXA Phantom
Ultrasound Table
Women’s Ultrasound EA Table
Adjustable Mobile Barrier
M-458
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to MedImaging.net and get access to news and events that shape the world of Radiology.
  • Free digital version edition of Medical Imaging International sent by email on regular basis
  • Free print version of Medical Imaging International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of Medical Imaging International in digital format
  • Free Medical Imaging International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Imaging IT

view channel
Image: QT Imaging’s latest breast imaging software adds enhanced reflection images by combining speed-of-sound and reflection data (photo courtesy of QT Imaging)

Breast Imaging Software Enhances Visualization and Tissue Characterization in Challenging Cases

Breast imaging can be particularly challenging in cases involving small breasts or implants, where image reconstruction and tissue characterization may be limited. Clinicians also need reproducible analysis... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.